Dmg Group, LLC Novo Nordisk A S Transaction History

Dmg Group, LLC

$115 Million
Q1 2024

A detailed history of Dmg Group, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Dmg Group, LLC holds 13,402 shares of NVO stock, worth $1.97 Million. This represents 1.49% of its overall portfolio holdings.

Number of Shares

13,402

Previous 12,451 7.64%

Holding current value

$1.97 Million

Previous $1.29 Million 33.54%

% of portfolio

1.49%

Previous 1.22%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	BUY	$102.11 - $135.92 $97,106 - $129,259	951 Added 7.64%	13,402 $1.72 Million
Q4 2023 Jan 10, 2024	SELL	$87.78 - $105.45 $236,215 - $283,765	-2,691 Reduced 17.77%	12,451 $1.29 Million
Q3 2023 Oct 26, 2023	BUY	$90.94 - $199.54 $721,608 - $1.58 Million	7,935 Added 110.1%	15,142 $1.38 Million
Q2 2023 Jul 13, 2023	SELL	$155.98 - $172.65 $144,905 - $160,391	-929 Reduced 11.42%	7,207 $1.17 Million
Q1 2023 Apr 24, 2023	SELL	$132.34 - $159.14 $35,070 - $42,172	-265 Reduced 3.15%	8,136 $1.3 Million

Q4 2022 Feb 06, 2023	SELL	$102.55 - $135.33 $2,358 - $3,112	-23 Reduced 0.27%	8,401 $1.15 Million
Q3 2022 Oct 27, 2022	SELL	$95.28 - $116.93 $16,102 - $19,761	-169 Reduced 1.97%	8,424 $864,000
Q2 2022 Aug 09, 2022	SELL	$103.24 - $121.81 $16,311 - $19,245	-158 Reduced 1.81%	8,593 $959,000
Q1 2022 Apr 25, 2022	SELL	$93.1 - $112.54 $479,185 - $579,243	-5,147 Reduced 37.03%	8,751 $969,000
Q4 2021 Jan 31, 2022	BUY	$95.88 - $117.08 $1.33 Million - $1.63 Million	13,898 New	13,898 $1.33 Million

Others Institutions Holding NVO

# of Institutions

1,852

Shares Held

309M

Call Options Held

5.29M

Put Options Held

4.93M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $332B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dmg Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dmg Group, LLC with notifications on news.

Account